258 related articles for article (PubMed ID: 23884639)
1. Gene signatures distinguish stage-specific prostate cancer stem cells isolated from transgenic adenocarcinoma of the mouse prostate lesions and predict the malignancy of human tumors.
Mazzoleni S; Jachetti E; Morosini S; Grioni M; Piras IS; Pala M; Bulfone A; Freschi M; Bellone M; Galli R
Stem Cells Transl Med; 2013 Sep; 2(9):678-89. PubMed ID: 23884639
[TBL] [Abstract][Full Text] [Related]
2. Re: Gene signatures distinguish stage-specific prostate cancer stem cells isolated from transgenic adenocarcinoma of the mouse prostate lesions and predict the malignancy of human tumors.
Atala A
J Urol; 2014 Apr; 191(4):1181. PubMed ID: 24703155
[No Abstract] [Full Text] [Related]
3. Galectin-3 in Prostate Cancer Stem-Like Cells Is Immunosuppressive and Drives Early Metastasis.
Caputo S; Grioni M; Brambillasca CS; Monno A; Brevi A; Freschi M; Piras IS; Elia AR; Pieri V; Baccega T; Lombardo A; Galli R; Briganti A; Doglioni C; Jachetti E; Bellone M
Front Immunol; 2020; 11():1820. PubMed ID: 33013832
[TBL] [Abstract][Full Text] [Related]
4. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of C-CAM cell adhesion molecule in prostate carcinogenesis in a transgenic mouse model.
Pu YS; Luo W; Lu HH; Greenberg NM; Lin SH; Gingrich JR
J Urol; 1999 Sep; 162(3 Pt 1):892-6. PubMed ID: 10458403
[TBL] [Abstract][Full Text] [Related]
6. Expression analysis of putative stem cell markers in human benign and malignant prostate.
Ugolkov AV; Eisengart LJ; Luan C; Yang XJ
Prostate; 2011 Jan; 71(1):18-25. PubMed ID: 20583131
[TBL] [Abstract][Full Text] [Related]
7. Safingol toxicology after oral administration to TRAMP mice: demonstration of safingol uptake and metabolism by N-acylation and N-methylation.
Morales PR; Dillehay DL; Moody SJ; Pallas DC; Pruett S; Allgood JC; Symolon H; Merrill AH
Drug Chem Toxicol; 2007; 30(3):197-216. PubMed ID: 17613006
[TBL] [Abstract][Full Text] [Related]
8. Development of PIN and prostate adenocarcinoma cell lines: a model system for multistage tumor progression.
Soares CR; Shibata MA; Green JE; Jorcyk CL
Neoplasia; 2002; 4(2):112-20. PubMed ID: 11896566
[TBL] [Abstract][Full Text] [Related]
9. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
Foster BA; Gingrich JR; Kwon ED; Madias C; Greenberg NM
Cancer Res; 1997 Aug; 57(16):3325-30. PubMed ID: 9269988
[TBL] [Abstract][Full Text] [Related]
10. Loss of survivin in the prostate epithelium impedes carcinogenesis in a mouse model of prostate adenocarcinoma.
Adisetiyo H; Liang M; Liao CP; Aycock-Williams A; Cohen MB; Xu S; Neamati N; Conway EM; Cheng CY; Nikitin AY; Roy-Burman P
PLoS One; 2013; 8(7):e69484. PubMed ID: 23936028
[TBL] [Abstract][Full Text] [Related]
11. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer.
Chiaverotti T; Couto SS; Donjacour A; Mao JH; Nagase H; Cardiff RD; Cunha GR; Balmain A
Am J Pathol; 2008 Jan; 172(1):236-46. PubMed ID: 18156212
[TBL] [Abstract][Full Text] [Related]
12. Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease.
Kang BH; Tavecchio M; Goel HL; Hsieh CC; Garlick DS; Raskett CM; Lian JB; Stein GS; Languino LR; Altieri DC
Br J Cancer; 2011 Feb; 104(4):629-34. PubMed ID: 21285984
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical implications.
Deng Q; Tang DG
Endocr Relat Cancer; 2015 Dec; 22(6):T209-20. PubMed ID: 26285606
[TBL] [Abstract][Full Text] [Related]
14. Expression and role of Foxa proteins in prostate cancer.
Mirosevich J; Gao N; Gupta A; Shappell SB; Jove R; Matusik RJ
Prostate; 2006 Jul; 66(10):1013-28. PubMed ID: 16001449
[TBL] [Abstract][Full Text] [Related]
15. Metabolic profiling of transgenic adenocarcinoma of mouse prostate (TRAMP) tissue by 1H-NMR analysis: evidence for unusual phospholipid metabolism.
Teichert F; Verschoyle RD; Greaves P; Edwards RE; Teahan O; Jones DJ; Wilson ID; Farmer PB; Steward WP; Gant TW; Gescher AJ; Keun HC
Prostate; 2008 Jul; 68(10):1035-47. PubMed ID: 18459103
[TBL] [Abstract][Full Text] [Related]
16. Androgen-independent prostate cancer progression in the TRAMP model.
Gingrich JR; Barrios RJ; Kattan MW; Nahm HS; Finegold MJ; Greenberg NM
Cancer Res; 1997 Nov; 57(21):4687-91. PubMed ID: 9354422
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer stem cells: deciphering the origins and pathways involved in prostate tumorigenesis and aggression.
Rybak AP; Bristow RG; Kapoor A
Oncotarget; 2015 Feb; 6(4):1900-19. PubMed ID: 25595909
[TBL] [Abstract][Full Text] [Related]
18. Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers.
Mauri G; Jachetti E; Comuzzi B; Dugo M; Arioli I; Miotti S; Sangaletti S; Di Carlo E; Tripodo C; Colombo MP
Oncotarget; 2016 Jan; 7(4):3905-20. PubMed ID: 26700622
[TBL] [Abstract][Full Text] [Related]
19. Hedgehog overexpression leads to the formation of prostate cancer stem cells with metastatic property irrespective of androgen receptor expression in the mouse model.
Chang HH; Chen BY; Wu CY; Tsao ZJ; Chen YY; Chang CP; Yang CR; Lin DP
J Biomed Sci; 2011 Jan; 18(1):6. PubMed ID: 21241512
[TBL] [Abstract][Full Text] [Related]
20. Deletion of p21/Cdkn1a confers protective effect against prostate tumorigenesis in transgenic adenocarcinoma of the mouse prostate model.
Jain AK; Raina K; Agarwal R
Cell Cycle; 2013 May; 12(10):1598-604. PubMed ID: 23624841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
